1. Introduction {#sec1-cancers-12-00958}
===============

Breast cancer (BC) prognosis depends not only on the tumor stage (localized versus metastatic disease), but also on the molecular subtype (luminal, HER2+, or triple-negative BC). Currently, BC management includes multidisciplinary and multimodal treatments: surgery, radiation therapy, chemotherapy, endocrine therapy and/or targeted therapies \[[@B1-cancers-12-00958],[@B2-cancers-12-00958]\]. Although some predictive and/or prognostic factors are available (for example, hormone receptor status, HER2 overexpression/amplification, histological grade or stage), additional predictive and prognostic biomarkers are needed to better adapt the treatment to each individual patient.

In the last few years, inflammatory blood markers have emerged as predictive and prognostic factors, particularly the neutrophil to lymphocyte ratio (NLR); that is, the ratio between the absolute neutrophil count and the absolute lymphocyte count. Lymphopenia and a high NLR before chemotherapy initiation have been inconsistently associated with worse responses to neo-adjuvant chemotherapy and with poor prognoses of different cancer types, including BC \[[@B3-cancers-12-00958],[@B4-cancers-12-00958]\].

The role of inflammation in cancer is now well established \[[@B5-cancers-12-00958]\], and has been described at different stages of cancer development (initiation, promotion, invasion, and metastasis). Activated inflammatory cells are sources of reactive oxygen species and reactive nitrogen intermediates that can induce DNA damage and genome instability, thus promoting cancer initiation \[[@B6-cancers-12-00958],[@B7-cancers-12-00958]\], or interfere with the DNA repair systems \[[@B8-cancers-12-00958]\]. Inflammation increases the production of growth factors and cytokines that can confer a stem cell-like phenotype to tumor progenitors. Inflammation also promotes upregulation of angiogenic factors (known as angiogenetic switch) that favor tumor progression.

Neutrophils have been the focus of much research, and there is now evidence that they can promote tumor growth and play a role in metastasis development \[[@B9-cancers-12-00958],[@B10-cancers-12-00958]\]. Their ability to secrete proteases, particularly matrix metalloproteases, contributes to favor a tumor's invasion. Neutrophils are also involved in tumor progression through their capacity to activate signal transducers and activators of transcription 3 (STAT3) and to promote neo-angiogenesis \[[@B11-cancers-12-00958]\].

In recent years, the role of tumor infiltrating lymphocytes (TILs), especially in BC, has also been studied \[[@B12-cancers-12-00958]\]. TILs are a selected population of T cells that show a high specific immunological reactivity against tumor cells. These lymphocytes, which are part of the innate immune system, can detect cancer cells and alert the immune system that will destroy them. Therefore, a low TIL count could be predictive of a lower response to neo-adjuvant chemotherapy \[[@B13-cancers-12-00958]\], and might be associated with poor prognosis \[[@B14-cancers-12-00958],[@B15-cancers-12-00958]\].

Peripheral inflammatory blood markers could be helpful for predicting patients' prognoses and also their response to neo-adjuvant chemotherapy in BC. Many studies evaluated the NLR, with conflicting results about its value as a predictive and/or prognostic factor \[[@B11-cancers-12-00958],[@B16-cancers-12-00958],[@B17-cancers-12-00958],[@B18-cancers-12-00958],[@B19-cancers-12-00958],[@B20-cancers-12-00958],[@B21-cancers-12-00958]\]. Studies on the total white blood cell count, neutrophil count, lymphocyte count and other blood cell ratios, such as the platelet to lymphocyte ratio (PLR), also gave inconsistent results.

Here, we systematically collected published data on the predictive or prognostic role of NLR in patients with BC.

We first summarized the published data on NLR and treatment efficacy, evaluated in terms of disease-free survival (DFS), breast cancer-specific survival (BCSS) and overall survival (OS), in patients with early BC (treated with neo-adjuvant or adjuvant chemotherapy) and with advanced BC. We also summarized the data on the predictive value of NLR for pathological complete response (PCR).

Then, we evaluated the correlation between chemotherapy-related toxicity and NLR and/or lymphopenia.

2. Material and Methods {#sec2-cancers-12-00958}
=======================

2.1. Search Strategy {#sec2dot1-cancers-12-00958}
--------------------

We performed a systematic search of the PubMed database using the following search terms: "neutrophil to lymphocytes ratio" or "lymphopenia" AND "breast cancer". We also looked for articles using the search terms "toxicity" AND "neutrophil to lymphocyte ratio" AND "breast cancer" and "toxicity" AND "lymphopenia" AND "breast cancer". We updated the literature search in February 2019. We also screened the references of the selected articles found in PubMed in order to ensure exhaustivity. We followed the PRISMA guidelines throughout the process.

2.2. Study Selection {#sec2dot2-cancers-12-00958}
--------------------

For the first part on NLR and treatment efficacy, we included all articles with only BC cohorts and PCR and/or survival analysis as the primary objectives. We excluded articles that concomitantly assessed different conditions (e.g., neo-adjuvant, adjuvant and metastatic settings). For the second part on toxicity, we included all articles reporting data on BC, inflammatory blood markers and chemotherapy-related toxicity. For both parts, we excluded all articles that were not in English ([Figure 1](#cancers-12-00958-f001){ref-type="fig"}).

2.3. Data Extraction {#sec2dot3-cancers-12-00958}
--------------------

Two reviewers independently extracted the following data from the selected studies: name of the first author and year of publication, population of interest, description of endpoints based on BC molecular subtypes, number of enrolled patients, ethnicity, treatment received, chosen NLR cut-off, primary objective and results (univariate analysis), results of subgroup analyses (if applicable), secondary objectives and their results, and multivariate analysis of NLR results (multivariate models and covariates used for adjustment). The two reviewers distinguished three populations: patients receiving neo-adjuvant chemotherapy, patients receiving adjuvant chemotherapy and patients with advanced BC.

For the studies on toxicity, the two reviewers selected articles on chemotherapy-related toxicity in the function of the lymphocyte count or NLR, and collected data on the population of interest, received treatments and toxicity.

If the selected articles also reported data on other inflammatory blood markers (e.g., lymphocyte count or PLR) as predictive and/or prognostic factors, we included this information in our tables.

2.4. Definitions {#sec2dot4-cancers-12-00958}
----------------

DFS was defined as the time from diagnosis (or the date of surgery for patients receiving adjuvant chemotherapy) to the date of relapse (local recurrence or metastases to distant sites) and/or death from any cause. In some papers, recurrence-free survival (RFS) was the primary objective. As RFS has the same definition as DFS, we used DFS for both DFS and RFS in this work.

BCSS was calculated from the date of diagnosis to the date of death by cancer or of the last follow-up visit. Some articles reported data on disease-specific survival (DSS), which has the same definition as BCSS. Therefore, we used the term BCSS for both BCSS and DSS in this work.

OS was defined as the time from the date of diagnosis (or the date of surgery) to the date of death due to any reason, or the date of the last follow-up (for some papers).

Progression-free survival (PFS) was defined as the time from treatment initiation to the date of disease progression, or death from any cause.

3. Results {#sec3-cancers-12-00958}
==========

3.1. NLR and Treatment Efficacy {#sec3dot1-cancers-12-00958}
-------------------------------

### 3.1.1. In Early BC {#sec3dot1dot1-cancers-12-00958}

#### (1) Patients Receiving Neo-Adjuvant Therapy

Ten studies reported data on NLR as a predictive or prognostic factor in patients receiving neo-adjuvant therapy \[[@B22-cancers-12-00958],[@B23-cancers-12-00958],[@B24-cancers-12-00958],[@B25-cancers-12-00958],[@B26-cancers-12-00958],[@B27-cancers-12-00958],[@B28-cancers-12-00958],[@B29-cancers-12-00958],[@B30-cancers-12-00958],[@B31-cancers-12-00958]\]. Among these studies, eight included patients with all molecular subtypes \[[@B22-cancers-12-00958],[@B23-cancers-12-00958],[@B24-cancers-12-00958],[@B25-cancers-12-00958],[@B26-cancers-12-00958],[@B27-cancers-12-00958],[@B28-cancers-12-00958],[@B29-cancers-12-00958]\], one included only patients with triple negative BC (TNBC) \[[@B31-cancers-12-00958]\] and the last one included only patients with hormone receptor-positive/HER2-negative BC \[[@B30-cancers-12-00958]\]. The NLR cut-off for the statistical analyses was between 1.7 and 3.33, and was computed by a receiver operating characteristic (ROC) curve analysis in all studies. The number of enrolled patients ranged from 78 to 373. Five studies reported data on Asian populations \[[@B23-cancers-12-00958],[@B25-cancers-12-00958],[@B28-cancers-12-00958],[@B30-cancers-12-00958],[@B31-cancers-12-00958]\]. In nine articles, the neo-adjuvant therapy protocols were described, and were based on anthracycline and/or taxane \[[@B23-cancers-12-00958],[@B24-cancers-12-00958],[@B25-cancers-12-00958],[@B26-cancers-12-00958],[@B27-cancers-12-00958],[@B28-cancers-12-00958],[@B29-cancers-12-00958],[@B30-cancers-12-00958],[@B31-cancers-12-00958]\]. ([Table 1](#cancers-12-00958-t001){ref-type="table"}).

##### Results on NLR and PCR

Studies including All BC Molecular Subtypes: the PCR rate in the function of NLR was the primary objective in seven studies \[[@B22-cancers-12-00958],[@B23-cancers-12-00958],[@B24-cancers-12-00958],[@B25-cancers-12-00958],[@B27-cancers-12-00958],[@B28-cancers-12-00958],[@B29-cancers-12-00958]\]. In all studies (except for two without definition), PCR was defined as the complete disappearance of invasive tumors in breast and lymph nodes (patients with residual ductal carcinoma in situ were also considered to have achieved PCR: ypT0/is pN0). Among these seven studies, only three (43%) found a significant correlation between NLR and PCR in the univariate analysis \[[@B23-cancers-12-00958],[@B25-cancers-12-00958],[@B28-cancers-12-00958]\]. Only Qian et al. analyzed data using a multivariate model and found that NLR was not an independent prognostic factor for PCR (*p* = 0.254) \[[@B28-cancers-12-00958]\].

Studies including Only Specific BC Molecular Subtypes: Chae et al. did not find any relation between NLR and PCR in the univariate and multivariate models (odds ratio (OR) = 4.274; 95%CI 1.451−12.658; *p* = 0.008) \[[@B31-cancers-12-00958]\] in 87 patients with TNBC.

Subgroup Analyses: Suppan et al. \[[@B24-cancers-12-00958]\] did not find any correlation between NLR and PCR in patients who received both anthracyclines and taxanes and in patients who received only anthracyclines or taxanes. They also compared the different BC molecular subtypes, and did not identify any correlation between NLR and PCR in any subtype.

Graziano et al. \[[@B27-cancers-12-00958]\] showed that PCR rates were higher in patients with NLR^low^/PLR^low^ than patients with NLR^high^/PLR^high^ (OR = 1.98; 95%CI 1.01--3.89; *p* = 0.044).

##### Results on NLR and DFS

Studies including All BC Molecular Subtypes: DFS was the primary objective in six studies \[[@B23-cancers-12-00958],[@B24-cancers-12-00958],[@B25-cancers-12-00958],[@B26-cancers-12-00958],[@B28-cancers-12-00958],[@B29-cancers-12-00958]\]. Only two (33%) found that a higher NLR was correlated with a shorter DFS in the univariate analysis \[[@B25-cancers-12-00958],[@B26-cancers-12-00958]\]. Three studies (50%) analyzed data on NLR and DFS by multivariate analyses \[[@B24-cancers-12-00958],[@B25-cancers-12-00958],[@B26-cancers-12-00958]\], and only one (33%) \[[@B25-cancers-12-00958]\] showed that NLR was an independent prognostic factor for DFS (hazard ratio (HR) = 1.57; 95%CI 1.05--3.57; *p* \< 0.05).

Studies including Only Specific BC Molecular Subtypes: Koh et al. \[[@B30-cancers-12-00958]\] reported that in patients with hormone receptor-positive/HER2- negative BC, NLR was an independent prognostic factor for DFS (HR = 3.87; 95%CI 1.64--9.14; *p* = 0.002).

Sub Group Analyses: Asano et al. \[[@B23-cancers-12-00958]\] showed that in the subgroup of patients with TNBC (*n* = 61), NLR was correlated with DFS in the univariate analysis, but was not an independent prognostic factor of DFS.

##### Results on NLR and OS and BCSS

Studies including All BC Molecular Subtypes: four studies evaluated NLR and OS by a univariate analysis \[[@B23-cancers-12-00958],[@B26-cancers-12-00958],[@B28-cancers-12-00958],[@B29-cancers-12-00958]\], and only one (25%) \[[@B26-cancers-12-00958]\] found a significant association between NLR and OS, but NLR was not an independent prognostic factor for OS (*p* = 0.543). On the other hand, Chen et al. \[[@B25-cancers-12-00958]\] showed that in patients with stage II and III BC (*n* = 215), NLR was an independent prognostic factor for BCSS (HR = 2.21; 95%CI 1.01--4.39; *p* \< 0.05).

Studies including Only Specific BC Molecular Subtypes: Koh et al. \[[@B30-cancers-12-00958]\] showed that in 157 patients with hormone receptor-positive/HER2-negative BC, NLR was an independent prognostic factor for OS (HR = 24.87; 95% CI 3.1--201.3; *p* = 0.003).

Sub Group Analyses: Koh et al. \[[@B30-cancers-12-00958]\] also found that the correlation between NLR and OS was stronger in patients with stage III BC than in patients with stage II BC.

##### Conclusion on NLR as Prognostic and Predictive Factor in Patients with Early BC Receiving Neo-Adjuvant Chemotherapy

Six articles reported the results of the multivariate analyses of the data on NLR and PCR, DFS or OS in patients receiving neo-adjuvant chemotherapy \[[@B24-cancers-12-00958],[@B25-cancers-12-00958],[@B26-cancers-12-00958],[@B28-cancers-12-00958],[@B30-cancers-12-00958],[@B31-cancers-12-00958]\]. NLR was correlated with PCR in one article \[[@B31-cancers-12-00958]\] (50% of *n* = 2), with DFS in two studies (50% of *n* = 4) \[[@B25-cancers-12-00958],[@B30-cancers-12-00958]\], with OS in two articles (50% of *n* = 4) \[[@B30-cancers-12-00958],[@B31-cancers-12-00958]\] and with BCSS in one article (100%) \[[@B25-cancers-12-00958]\]. These analyses included a total of 1558 patients. The conclusion should be taken with caution because two of these six selected studies included only one molecular subtype (TNBC or hormone receptor-positive/HER2 negative BC). [Table 2](#cancers-12-00958-t002){ref-type="table"} summarizes the results of these multivariate analyses and the adjustment factors.

##### Results on other Inflammatory Blood Markers

Among these studies, four \[[@B26-cancers-12-00958],[@B27-cancers-12-00958],[@B28-cancers-12-00958],[@B29-cancers-12-00958]\] also evaluated the total lymphocyte count (*n* = 2) \[[@B26-cancers-12-00958],[@B28-cancers-12-00958]\] or total neutrophil count before treatment (*n* = 2) \[[@B26-cancers-12-00958],[@B28-cancers-12-00958]\], and other ratios, such as the lymphocyte to monocyte ratio (LMR) (*n* = 2) \[[@B26-cancers-12-00958],[@B29-cancers-12-00958]\], neutrophil to monocyte ratio (NMR) (*n* = 2) \[[@B26-cancers-12-00958],[@B29-cancers-12-00958]\] and PLR (*n* = 2) \[[@B27-cancers-12-00958],[@B29-cancers-12-00958]\], as predictive and prognostic factors of survival. Lymphocyte count was not correlated with DFS and OS in the study by Marin Hernandez et al. \[[@B26-cancers-12-00958]\], whereas it was an independent predictive factor for PCR in the multivariate analysis in the work by Qian et al. (OR = 4.37; 95%CI 1.43--13.39; *p* = 0.01) \[[@B28-cancers-12-00958]\]. Neutrophil count was not correlated with PCR and OS in the studies by Qian et al. \[[@B28-cancers-12-00958]\] and by Marin Hernandez et al. \[[@B26-cancers-12-00958]\], respectively. Conversely, it was an independent prognostic factor for DFS (multivariate analysis) in the study by Qian et al. \[[@B28-cancers-12-00958]\]. PLR was not correlated with PCR \[[@B27-cancers-12-00958]\], DFS or OS \[[@B29-cancers-12-00958]\] (univariate analyses). Similarly, NMR and LMR were not correlated with survival (DFS and OS) in the study by Marin Hernandez et al. (univariate and multivariate analyses) \[[@B26-cancers-12-00958]\] and also in the study by Losada et al. (univariate analysis) \[[@B29-cancers-12-00958]\].

#### (2) Patients Receiving Adjuvant Treatment

Twenty-three studies reported data on NLR as a prognostic factor in patients with localized BC receiving adjuvant treatment \[[@B32-cancers-12-00958],[@B33-cancers-12-00958],[@B34-cancers-12-00958],[@B35-cancers-12-00958],[@B36-cancers-12-00958],[@B37-cancers-12-00958],[@B38-cancers-12-00958],[@B39-cancers-12-00958],[@B40-cancers-12-00958],[@B41-cancers-12-00958],[@B42-cancers-12-00958],[@B43-cancers-12-00958],[@B44-cancers-12-00958],[@B45-cancers-12-00958],[@B46-cancers-12-00958],[@B47-cancers-12-00958],[@B48-cancers-12-00958],[@B49-cancers-12-00958],[@B50-cancers-12-00958],[@B51-cancers-12-00958],[@B52-cancers-12-00958],[@B53-cancers-12-00958]\]. Most studies (*n* = 18; 78%) included patients with all BC molecular subtypes \[[@B32-cancers-12-00958],[@B33-cancers-12-00958],[@B34-cancers-12-00958],[@B35-cancers-12-00958],[@B36-cancers-12-00958],[@B37-cancers-12-00958],[@B38-cancers-12-00958],[@B39-cancers-12-00958],[@B40-cancers-12-00958],[@B41-cancers-12-00958],[@B42-cancers-12-00958],[@B43-cancers-12-00958],[@B44-cancers-12-00958],[@B45-cancers-12-00958],[@B46-cancers-12-00958],[@B47-cancers-12-00958],[@B48-cancers-12-00958]\]. four included only patients withTNBC \[[@B49-cancers-12-00958],[@B50-cancers-12-00958],[@B51-cancers-12-00958],[@B52-cancers-12-00958]\], and one work included patients with onlyhormone receptor-negative BC (independently of the HER2 status) \[[@B53-cancers-12-00958]\]. The NLR cut-off for the statistical analyses, computed by the ROC curves analysis in 78% of these studies, was between 1.34 and 4. The number of enrolled patients varied from 90 to 1570. Fifteen studies (65%) reported data on Asian populations \[[@B32-cancers-12-00958],[@B35-cancers-12-00958],[@B36-cancers-12-00958],[@B38-cancers-12-00958],[@B39-cancers-12-00958],[@B42-cancers-12-00958],[@B43-cancers-12-00958],[@B44-cancers-12-00958],[@B46-cancers-12-00958],[@B47-cancers-12-00958],[@B48-cancers-12-00958],[@B49-cancers-12-00958],[@B51-cancers-12-00958],[@B53-cancers-12-00958]\]. The adjuvant chemotherapy regimens were described only in six studies (anthracycline- and/or taxane-based regimens) \[[@B33-cancers-12-00958],[@B38-cancers-12-00958],[@B43-cancers-12-00958],[@B45-cancers-12-00958],[@B48-cancers-12-00958],[@B51-cancers-12-00958]\]. ([Table 3](#cancers-12-00958-t003){ref-type="table"}).

##### Results on NLR and DFS

Studies including All BC Molecular Subtypes: seventeen studies analyzed the correlation between NLR and DFS after adjuvant chemotherapy \[[@B33-cancers-12-00958],[@B34-cancers-12-00958],[@B35-cancers-12-00958],[@B36-cancers-12-00958],[@B37-cancers-12-00958],[@B38-cancers-12-00958],[@B39-cancers-12-00958],[@B40-cancers-12-00958],[@B41-cancers-12-00958],[@B42-cancers-12-00958],[@B43-cancers-12-00958],[@B44-cancers-12-00958],[@B45-cancers-12-00958],[@B46-cancers-12-00958],[@B47-cancers-12-00958]\]. In the univariate analysis, NLR was correlated with DFS in 14/17 articles (82%) \[[@B34-cancers-12-00958],[@B35-cancers-12-00958],[@B37-cancers-12-00958],[@B38-cancers-12-00958],[@B39-cancers-12-00958],[@B40-cancers-12-00958],[@B41-cancers-12-00958],[@B42-cancers-12-00958],[@B44-cancers-12-00958],[@B45-cancers-12-00958],[@B46-cancers-12-00958],[@B46-cancers-12-00958],[@B47-cancers-12-00958]\]. Among the 13 studies where multivariate models were used \[[@B34-cancers-12-00958],[@B35-cancers-12-00958],[@B37-cancers-12-00958],[@B38-cancers-12-00958],[@B39-cancers-12-00958],[@B40-cancers-12-00958],[@B41-cancers-12-00958],[@B42-cancers-12-00958],[@B44-cancers-12-00958],[@B46-cancers-12-00958],[@B47-cancers-12-00958],[@B48-cancers-12-00958]\], only eight found that NLR was an independent prognostic factor for DFS \[[@B34-cancers-12-00958],[@B37-cancers-12-00958],[@B38-cancers-12-00958],[@B39-cancers-12-00958],[@B40-cancers-12-00958],[@B46-cancers-12-00958],[@B48-cancers-12-00958]\].

Studies in Specific BC Molecular Subgroups: four studies reported data on patients with TNBC \[[@B49-cancers-12-00958],[@B50-cancers-12-00958],[@B51-cancers-12-00958],[@B52-cancers-12-00958]\]. Three (75%) showed that a high NLR was correlated with a shorter DFS in the univariate analyses \[[@B49-cancers-12-00958],[@B50-cancers-12-00958],[@B51-cancers-12-00958]\]. In the multivariate analyses, two studies found a statistically significant correlation between NLR and DFS in patients with TNBC receiving adjuvant chemotherapy \[[@B49-cancers-12-00958],[@B50-cancers-12-00958]\].

In patients with hormone receptor-negative BC, Liu et al. \[[@B53-cancers-12-00958]\] found a correlation between NLR and DFS in the univariate and multivariate analyses (HR = 1.89; 95%CI 1.42--2.51; *p* \< 0.001).

Subgroup Analyses: many studies reported subgroup analyses based on the BC stage, molecular or pathological subtypes. Five studies tried to determine whether the results varied in the function of the molecular subtypes \[[@B32-cancers-12-00958],[@B38-cancers-12-00958],[@B39-cancers-12-00958],[@B44-cancers-12-00958],[@B46-cancers-12-00958]\]. In two studies, NLR was correlated with DFS (and to DSS) only in patients with luminal cancer \[[@B44-cancers-12-00958]\] and luminal A cancer \[[@B32-cancers-12-00958]\]. Conversely, in two other studies, this correlation was observed only in patients with TNBC \[[@B38-cancers-12-00958],[@B39-cancers-12-00958]\]. Another article reported that NRL was correlated with DFS in all molecular subtypes \[[@B46-cancers-12-00958]\].

Moreover, in patients with lymph node invasion, NLR was correlated with DFS, but only in the univariate analysis \[[@B44-cancers-12-00958]\].

Finally, two studies \[[@B45-cancers-12-00958],[@B46-cancers-12-00958]\] showed that NLR was correlated with DFS in early stage BC (I and/or II according to the AJCC staging system), but not in stage III BC.

##### Results on NLR and OS and BCSS

Studies including all BC Molecular Subtypes: among the 10 studies with data on the NLR and OS in patients receiving adjuvant treatment \[[@B33-cancers-12-00958],[@B34-cancers-12-00958],[@B36-cancers-12-00958],[@B37-cancers-12-00958],[@B38-cancers-12-00958],[@B39-cancers-12-00958],[@B41-cancers-12-00958],[@B42-cancers-12-00958],[@B45-cancers-12-00958],[@B47-cancers-12-00958]\], six (60%) found a correlation in the univariate analysis \[[@B34-cancers-12-00958],[@B36-cancers-12-00958],[@B37-cancers-12-00958],[@B39-cancers-12-00958],[@B41-cancers-12-00958],[@B45-cancers-12-00958]\]. Five studies analyzed the correlation between NLR and OS by a multivariate analysis \[[@B34-cancers-12-00958],[@B36-cancers-12-00958],[@B37-cancers-12-00958],[@B39-cancers-12-00958],[@B41-cancers-12-00958]\], and four (80%) found that NLR was an independent prognostic factor for OS \[[@B34-cancers-12-00958],[@B36-cancers-12-00958],[@B37-cancers-12-00958],[@B39-cancers-12-00958]\]. Three studies with data on the NLR and BCSS \[[@B32-cancers-12-00958],[@B35-cancers-12-00958],[@B44-cancers-12-00958]\] showed that they were correlated (univariate analyses), and two (66%) identified NLR as an independent prognostic factor for BCSS \[[@B32-cancers-12-00958],[@B35-cancers-12-00958]\].

Studies including Specific BC Molecular Subtypes: four studies assessed OS in the function of the NLR in patients with TNBC \[[@B49-cancers-12-00958],[@B50-cancers-12-00958],[@B51-cancers-12-00958],[@B52-cancers-12-00958]\]. Three (75%) showed that a high NLR was correlated with a shorter OS (univariate analysis) \[[@B49-cancers-12-00958],[@B50-cancers-12-00958],[@B51-cancers-12-00958]\]. They also found a significant correlation between NLR and OS (multivariate analysis) in patients with TNBC receiving adjuvant chemotherapy \[[@B49-cancers-12-00958],[@B50-cancers-12-00958],[@B51-cancers-12-00958]\]. Liu et al. \[[@B53-cancers-12-00958]\] found that in patients with hormone receptor-negative BC, a high NLR was associated with a poor OS in the univariate (HR = 3.09; 95%CI 2.35--4.06; *p* \< 0.001) and multivariate analyses (HR = 3.09; 95%CI 2.35--4.06; *p* \< 0.001).

Subgroup Analyses: NLR was correlated with OS in the luminal A and TNBC subgroups in the study by Yao et al. \[[@B36-cancers-12-00958]\], but only in the TNBC subgroup in the work by Jia et al. \[[@B39-cancers-12-00958]\].

##### Conclusion on NLR as Prognostic Factor in Patients with Localized BC Receiving Adjuvant Chemotherapy

Twenty-three articles reported data on NLR as a prognostic factor in patients receiving adjuvant treatment \[[@B32-cancers-12-00958],[@B33-cancers-12-00958],[@B34-cancers-12-00958],[@B35-cancers-12-00958],[@B36-cancers-12-00958],[@B37-cancers-12-00958],[@B38-cancers-12-00958],[@B39-cancers-12-00958],[@B40-cancers-12-00958],[@B41-cancers-12-00958],[@B42-cancers-12-00958],[@B43-cancers-12-00958],[@B44-cancers-12-00958],[@B45-cancers-12-00958],[@B46-cancers-12-00958],[@B47-cancers-12-00958],[@B48-cancers-12-00958],[@B49-cancers-12-00958],[@B50-cancers-12-00958],[@B51-cancers-12-00958],[@B52-cancers-12-00958],[@B53-cancers-12-00958]\]. Among the 29 multivariate analyses performed in these studies, 21 (72.4%) highlighted a positive correlation between NLR and survival \[[@B32-cancers-12-00958],[@B34-cancers-12-00958],[@B35-cancers-12-00958],[@B36-cancers-12-00958],[@B37-cancers-12-00958],[@B38-cancers-12-00958],[@B39-cancers-12-00958],[@B40-cancers-12-00958],[@B46-cancers-12-00958],[@B48-cancers-12-00958],[@B49-cancers-12-00958],[@B50-cancers-12-00958],[@B51-cancers-12-00958],[@B53-cancers-12-00958]\], specifically DFS (11/17 analyses; 65%) \[[@B34-cancers-12-00958],[@B37-cancers-12-00958],[@B38-cancers-12-00958],[@B39-cancers-12-00958],[@B40-cancers-12-00958],[@B46-cancers-12-00958],[@B48-cancers-12-00958],[@B49-cancers-12-00958],[@B50-cancers-12-00958],[@B53-cancers-12-00958]\], OS (8/9 analyses; 89%) \[[@B34-cancers-12-00958],[@B36-cancers-12-00958],[@B37-cancers-12-00958],[@B39-cancers-12-00958],[@B49-cancers-12-00958],[@B50-cancers-12-00958],[@B51-cancers-12-00958],[@B53-cancers-12-00958]\] and BCSS (2/3; 66%) \[[@B32-cancers-12-00958],[@B35-cancers-12-00958]\]. In total, 18,153 patients were enrolled in these studies. [Table 4](#cancers-12-00958-t004){ref-type="table"} summarizes the results of the multivariate analyses and the adjustment factors used.

##### Results on Other Inflammatory Blood Markers

Eleven studies reported results on other inflammatory blood markers. PLR was correlated with DFS in four \[[@B41-cancers-12-00958],[@B43-cancers-12-00958],[@B44-cancers-12-00958],[@B53-cancers-12-00958]\] of the six (66.6%) studies that assessed this correlation \[[@B33-cancers-12-00958],[@B36-cancers-12-00958],[@B41-cancers-12-00958],[@B43-cancers-12-00958],[@B44-cancers-12-00958],[@B53-cancers-12-00958]\], and with OS in two \[[@B41-cancers-12-00958],[@B53-cancers-12-00958]\] of the four (50%) studies that focused on this question \[[@B33-cancers-12-00958],[@B36-cancers-12-00958],[@B41-cancers-12-00958],[@B53-cancers-12-00958]\]. PLR was correlated with DSS in the study by Cho et al. \[[@B44-cancers-12-00958]\]. Four articles \[[@B41-cancers-12-00958],[@B43-cancers-12-00958],[@B44-cancers-12-00958],[@B53-cancers-12-00958]\] evaluated PLR in multivariate analyses. Three (75% of four) found that PLR was an independent prognostic factor for DFS \[[@B41-cancers-12-00958],[@B43-cancers-12-00958],[@B44-cancers-12-00958]\], one (50% of two) found a correlation between PLR and OS \[[@B41-cancers-12-00958]\] and one with DSS (100%; only one study) \[[@B44-cancers-12-00958]\].

Two studies found that a derived NLR (dNLR, calculated as the ratio of neutrophils over white blood cells minus neutrophils) was correlated with DFS, OS and DSS in the univariate analyses \[[@B37-cancers-12-00958],[@B44-cancers-12-00958]\], but not in the multivariate analyses \[[@B44-cancers-12-00958]\].

LMR was correlated with DFS, OS and DSS (univariate analysis) in two \[[@B39-cancers-12-00958],[@B44-cancers-12-00958]\] of the three studies that assessed this biomarker \[[@B39-cancers-12-00958],[@B43-cancers-12-00958],[@B44-cancers-12-00958]\]. In the multivariate analyses, no correlation was found between LMR and survival.

Among the four studies on lymphocyte count and survival \[[@B33-cancers-12-00958],[@B44-cancers-12-00958],[@B47-cancers-12-00958],[@B52-cancers-12-00958]\], only one (25%) found that lymphocyte count was correlated with DFS and DSS \[[@B44-cancers-12-00958]\], but never with OS. No multivariate analysis was performed.

Finally, two studies \[[@B33-cancers-12-00958],[@B44-cancers-12-00958]\] showed that neutrophil count, platelet count, and monocyte count were not correlated with survival. Cihan et al. \[[@B33-cancers-12-00958]\] also reported no correlation between white blood cell count, eosinophil cell count, basophil cell count and survival (univariate analyses).

### 3.1.2. Patients with Advanced Breast Cancer {#sec3dot1dot2-cancers-12-00958}

We identified eight studies with data on NLR as a prognostic factor in patients with metastatic BC \[[@B54-cancers-12-00958],[@B55-cancers-12-00958],[@B56-cancers-12-00958],[@B57-cancers-12-00958],[@B58-cancers-12-00958],[@B59-cancers-12-00958],[@B60-cancers-12-00958],[@B61-cancers-12-00958]\]. Four articles (50%) enrolled patients with all molecular subtypes \[[@B54-cancers-12-00958],[@B56-cancers-12-00958],[@B57-cancers-12-00958],[@B58-cancers-12-00958]\], two focused on patients with HER2-positive BC \[[@B55-cancers-12-00958],[@B61-cancers-12-00958]\], one on patients with TNBC \[[@B60-cancers-12-00958]\] and one on patients with hormone receptor-positive BC receiving hormone therapy as initial treatment \[[@B59-cancers-12-00958]\]([Table 5](#cancers-12-00958-t005){ref-type="table"}).

In these studies, the NLR cut-off value ranged from 1.9 to 3 (always based on previous studies), and the number of enrolled patients varied between 34 and 171. Six studies (75%) reported data on Asian populations \[[@B54-cancers-12-00958],[@B55-cancers-12-00958],[@B56-cancers-12-00958],[@B58-cancers-12-00958],[@B59-cancers-12-00958],[@B61-cancers-12-00958]\].

#### (1) Results on NLR and PFS

Studies including All BC Molecular Subtypes: two studies reported data on NLR and PFS \[[@B56-cancers-12-00958],[@B57-cancers-12-00958]\] and one (50%) showed that NLR was an independent prognostic factor for PFS (HR = 0.39; 95%CI 0.18−0.78; *p* \< 0.001) \[[@B56-cancers-12-00958]\].

Studies including only Specific BC Molecular Subtypes: Vernieri et al. \[[@B60-cancers-12-00958]\] showed that in 57 patients with TNBC, NLR was an independent prognostic factor for PFS (HR = 2.65; 95%CI 1.36--5.18; *p* = 0.004). Two studies focused on patients with HER2-positive tumors \[[@B55-cancers-12-00958],[@B61-cancers-12-00958]\], and one found that NLR was correlated with PFS in the multivariate analysis (HR = 0.27; 95%CI 0.10--0.63; *p* \< 0.001) \[[@B61-cancers-12-00958]\]. NLR was an independent prognostic factor for PFS in patients with hormone receptor-positive BC receiving endocrine therapy as initial treatment (HR = 3.93; 95%CI 1.4--10.84; *p* = 0.008) \[[@B59-cancers-12-00958]\].

#### (2) Results on NLR and OS

Studies including All Molecular Subtypes: among the three studies with data on NLR and OS \[[@B54-cancers-12-00958],[@B56-cancers-12-00958],[@B58-cancers-12-00958]\], two (66%) \[[@B54-cancers-12-00958]\] found that NLR was an independent prognostic factor for OS in patients with metastatic BC.

Studies including Only Specific BC Molecular Subtypes: NRL was correlated with OS in patients with HER2-positive BC, in the univariate and multivariate analyses (HR = 0.35; 95%CI 0.13--0.84; *p* = 0.018) \[[@B61-cancers-12-00958]\], and also in patients with hormone receptor-positive in the univariate analysis (multivariate results not available) \[[@B59-cancers-12-00958]\].

#### (3) Conclusion on NLR as Prognostic Factor in Patients with Advanced BC

Six articles reported the results of the multivariate analyses on NLR and survival in patients with advanced BC \[[@B54-cancers-12-00958],[@B56-cancers-12-00958],[@B58-cancers-12-00958],[@B59-cancers-12-00958],[@B60-cancers-12-00958],[@B61-cancers-12-00958]\]. All found a significant correlation between NLR and survival. However, such results should be considered with caution because the multivariate analyses did not concern all types of survival outcomes and the studied populations were very heterogeneous. [Table 6](#cancers-12-00958-t006){ref-type="table"} summarizes the results of the multivariate analyses and the adjustment factors used.

#### (4) Results for Other Inflammatory Blood Markers

Three articles had data on other inflammatory blood markers as prognostic factors for survival in advanced BC \[[@B55-cancers-12-00958],[@B60-cancers-12-00958],[@B61-cancers-12-00958]\]. In the univariate analysis, PFS was correlated with the absolute lymphocyte count, PLR and LMR \[[@B55-cancers-12-00958],[@B60-cancers-12-00958]\]; however, one study found no correlation between PLR and PFS \[[@B61-cancers-12-00958]\]. Vernieri et al. \[[@B60-cancers-12-00958]\] found that in the multivariate analysis, PLR was an independent prognostic factor for PFS. One analysis showed that PLR was not a prognostic factor for OS \[[@B61-cancers-12-00958]\].

3.2. Toxicity {#sec3dot2-cancers-12-00958}
-------------

We identified four articles that reported data on inflammatory blood markers and treatment-related toxicity \[[@B62-cancers-12-00958],[@B63-cancers-12-00958],[@B64-cancers-12-00958],[@B65-cancers-12-00958]\] as the primary objective. Only one study analyzed the correlation between NLR and toxicity in a cohort of patients with BC (Yamanouchi et al. \[[@B65-cancers-12-00958]\]). The three other studies focused on lymphopenia (defined as lymphocytes value \< 0.7 G/L) in a cohort of patients with different cancer types (including BC). Two studies evaluated a French population \[[@B62-cancers-12-00958],[@B63-cancers-12-00958]\], and the other two concerned Asian patients \[[@B64-cancers-12-00958],[@B65-cancers-12-00958]\]. ([Table 7](#cancers-12-00958-t007){ref-type="table"}).

Ray Coquard et al. \[[@B62-cancers-12-00958]\] evaluated the predictive factors for early death after chemotherapy (defined as death within one month after the administration of cancer treatment) in a prospective study. They included 1051 patients among whom 756 (33%) had BC. They found that lymphopenia was a predictive factor of worse survival, in the univariate and multivariate models (OR = 3.1; 95%CI 1.8--5.8; *p* \< 0.001). In a successive article, the same authors \[[@B63-cancers-12-00958]\] determined whether a lymphocyte count \<0.7 G/L at day 1 was predictive of febrile neutropenia in three cohorts of 950, 321 and 329 patients (including the cohort used in the previous work) among whom 24%, 33% and 42% had BC, respectively. They found that in the largest cohort, a lymphocyte count \<0.7 G/L at day 1 was predictive of febrile neutropenia in the univariate and multivariate analyses (OR = 1.75; 95%CI 1.49--4.8; *p* = 0.02).

A Korean study \[[@B64-cancers-12-00958]\] on 82 patients (including 11 (13%) patients with BC) did not find any correlation between lymphopenia at day 1 of the first chemotherapy course and risk of febrile neutropenia. However, due to the small number of patients with BC, no definitive conclusion could be drawn for this population.

Finally, Yamanouchi et al. \[[@B65-cancers-12-00958]\] did not find any correlation between peripheral neuropathy occurrence and NLR, PLR or MLR in a cohort of 67 patients with BC who received at least four cycles of docetaxel (75 mg/m^2^).

4. Conclusions {#sec4-cancers-12-00958}
==============

We report here a comprehensive and exhaustive overview of the published literature on NLR as a predictive and/or prognostic factor in patients with BC.

This analysis indicates that NLR is a reliable prognostic factor in localized BC treated with adjuvant chemotherapy. Indeed, in the 21/29 analyses (72.4%) where multivariate models were used, NLR was independently correlated with survival (DFS, BCSS and/or OS) \[[@B32-cancers-12-00958],[@B34-cancers-12-00958],[@B35-cancers-12-00958],[@B36-cancers-12-00958],[@B37-cancers-12-00958],[@B38-cancers-12-00958],[@B39-cancers-12-00958],[@B40-cancers-12-00958],[@B46-cancers-12-00958],[@B48-cancers-12-00958],[@B49-cancers-12-00958],[@B50-cancers-12-00958],[@B51-cancers-12-00958],[@B53-cancers-12-00958]\].

Results are less clear-cut for patients with a localized disease receiving neo-adjuvant chemotherapy because only two of four studies (50%) found a correlation between NLR and DFS \[[@B25-cancers-12-00958],[@B30-cancers-12-00958]\], and one of two studies (50%) found a correlation between NLR and OS \[[@B30-cancers-12-00958]\]. The only study that analyzed NLR and BCSS found a significant correlation \[[@B25-cancers-12-00958]\]. Conclusions on NLR and PCR in this population cannot be drawn because only one of two studies (50%) found a correlation between these factors \[[@B31-cancers-12-00958]\].

Some heterogeneity in the NLR results in the neo-adjuvant chemotherapy setting could be linked to the different results observed in the different molecular subtypes (positive correlation only in patients with TNBC) and also to the small patient samples. Indeed, the total number of patients enrolled in the selected studies in this setting was 1558, compared with 18,153 patients in the adjuvant chemotherapy setting.

Fewer data have been published on patients with metastatic BC. NLR appears to be a good prognostic factor for PFS and OS in this population, although studies are hard to compare due to the population heterogeneity \[[@B54-cancers-12-00958],[@B56-cancers-12-00958],[@B58-cancers-12-00958],[@B59-cancers-12-00958],[@B60-cancers-12-00958],[@B61-cancers-12-00958]\] (i.e., BC molecular features, treatment type, number of previous chemotherapy courses). Therefore, no firm conclusion can be made on inflammatory blood markers as prognostic factors in patients with metastatic BC.

Only very few studies focused on NLR or lymphopenia as predictive factors of chemotherapy-related toxicity \[[@B62-cancers-12-00958],[@B63-cancers-12-00958],[@B64-cancers-12-00958],[@B65-cancers-12-00958]\]. Lymphopenia at day 1 of treatment was correlated with early death after chemotherapy \[[@B62-cancers-12-00958]\]. However, no definitive conclusion could be made for patients with BC because the studied population included patients with various cancer types, and no specific subgroup analysis was performed in the BC subgroup. Lymphopenia at day 1 was inconsistently correlated with febrile neutropenia (two studies with opposite results \[[@B63-cancers-12-00958],[@B64-cancers-12-00958]\]), and NLR was not correlated with peripheral neuropathy in patients receiving docetaxel \[[@B65-cancers-12-00958]\]. Additional studies with larger populations should be performed to bring more data on NLR/lymphopenia as predictive factors of treatment toxicity.

Due to its worse prognosis and higher chemosensitivity, TNBC was the most extensively evaluated molecular subgroup. Indeed, the results of the subgroup analyses on TNBC were reported in 10 studies \[[@B23-cancers-12-00958],[@B24-cancers-12-00958],[@B32-cancers-12-00958],[@B36-cancers-12-00958],[@B38-cancers-12-00958],[@B39-cancers-12-00958],[@B46-cancers-12-00958],[@B53-cancers-12-00958],[@B56-cancers-12-00958]\]. Most of them (80%) found a correlation between NLR and survival in this subgroup \[[@B23-cancers-12-00958],[@B36-cancers-12-00958],[@B38-cancers-12-00958],[@B39-cancers-12-00958],[@B46-cancers-12-00958],[@B53-cancers-12-00958],[@B56-cancers-12-00958]\], a much higher proportion of positive results than for the other BC subgroups, possibly related to TNBC-specific clinical history.

Notably, most of the selected studies (33/41) evaluated Asian patients \[[@B23-cancers-12-00958],[@B25-cancers-12-00958],[@B28-cancers-12-00958],[@B30-cancers-12-00958],[@B31-cancers-12-00958],[@B32-cancers-12-00958],[@B35-cancers-12-00958],[@B36-cancers-12-00958],[@B38-cancers-12-00958],[@B39-cancers-12-00958],[@B42-cancers-12-00958],[@B43-cancers-12-00958],[@B44-cancers-12-00958],[@B46-cancers-12-00958],[@B47-cancers-12-00958],[@B48-cancers-12-00958],[@B49-cancers-12-00958],[@B51-cancers-12-00958],[@B53-cancers-12-00958],[@B54-cancers-12-00958],[@B55-cancers-12-00958],[@B56-cancers-12-00958],[@B58-cancers-12-00958],[@B59-cancers-12-00958],[@B61-cancers-12-00958],[@B64-cancers-12-00958],[@B65-cancers-12-00958]\]. This demographic variable could be associated with specific molecular and pharmacological features that might lead to differences in the treatment toxicity and efficacy profiles. Another limitation concerns HER2-positive BC. Indeed, the use of anti-HER2 targeted therapy was inconsistently reported, leading to heterogeneity in survival predictions for this subgroup (not very clear). Considering these population-based sources of confusion, a large, multi-ethnic study should be carried out to evaluate, worldwide and for each world region, the prognostic and predictive value of NLR and other inflammatory blood markers in patients with BC.

Another limitation concerns the drugs used in the neo-adjuvant and adjuvant settings. Although most studies reported the use of anthracyclines and/or taxanes, only 47% of them (16/34) described the sequential or concomitant use of anthracycline- and taxane-based regimens, as recommended by the international learned societies. Data on chemotherapy regimens were missing in 53% of the studies (18/34).

Finally, all selected studies had a retrospective design. Although in most of them (\>75%) at least one multivariate analysis was carried out, these results need to be validated in prospective studies or by retrospective evaluation in a prospective clinical trial.

In conclusion, NLR appears to be a prognostic factor for DFS and OS in patients with early BC receiving adjuvant chemotherapy. Additional investigations in prospective studies would strengthen these results. On the other hand, the correlation between NLR and survival in neo-adjuvant chemotherapy settings remains unclear because most studies failed to show evidence of an independent correlation. Finally, most of the available data show that NLR is not a predictive factor for PCR in patients treated with neo-adjuvant chemotherapy; however, due to the population heterogeneity and/or small sample size of the published studies on this question, dedicated clinical trials are needed.
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BC

breast cancer

BCSS

breast cancer specific survival

dNLR

derived neutrophil to lymphocyte ratio

DFS

disease free survival

DSS

disease specific survival

ER

estrogen receptor

ET

endocrine therapy

HR

hazard ratio

LMR

lymphocyte to monocyte ratio

MCH

mean corpuscular hemoglobin

NI

not indicated

NLR

neutrophil to lymphocyte ratio

NMR

neutrophil to monocyte ratio

NSAIDs

non-steroidal anti-inflammatory drugs

OR

Odd ratio

OS

overall survival

PCR

pathological complete response

PLR

platelet to lymphocyte ratio

PR

progesterone receptor

RDW

red cell distribution

RFS

recurrence free survival

TILs

tumor infiltrating lymphocytes

TNBC

triple negative breast cancer
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cancers-12-00958-t001_Table 1

###### 

Articles including data on neutrophil to lymphocyte ratio (NLR) as predictive and prognostic factor in patients with early breast cancer (BC) receiving neo-adjuvant chemotherapy.

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  First Author                  Number of Patients                      Treatment                                                                                                                Primary Objective                              Cut-Off                                      Primary Objective Results (Univariate Analysis)                                                        Results of Multivariate Models
  ----------------------------- --------------------------------------- ------------------------------------------------------------------------------------------------------------------------ ---------------------------------------------- -------------------------------------------- ------------------------------------------------------------------------------------------------------ ----------------------------------------
  Eryilmaz 2014\                78 patients:\                           NS                                                                                                                       NLR as predictive factor for PCR               2.33                                         −NLR and PCR                                                                                           
  \[[@B22-cancers-12-00958]\]   all BC molecular subtypes                                                                                                                                                                                                                                                                                                                                           

  Asano 2016\                   177 patients:\                          Anthracyclines + taxanes                                                                                                 NLR as predictive and prognostic factor        3 (chosen before the statistical analysis)   −NLR and DFS (*p* = 0.849)\                                                                            
  \[[@B23-cancers-12-00958]\]   116 non TNBC (65.5%)\                                                                                                                                                                                                                                        −NLR and OS (*p* = 0.965)\                                                                             
                                61 TNBC (34.5%)                                                                                                                                                                                                                                              PCR was achieved in 28.6% of patients with high NLR vs 56.9% of patients with low NLR (*p* \< 0.001)   

  Suppan 2015\                  247 patients:\                          Anthracyclines + taxanes (58.3%); anthracyclines (38.2%); taxanes (2.8%); other (6.1%)                                   NLR as predictive and prognostic factor        Comparison of median NLR                     −NLR and DFS (*p* = 0.363)\                                                                            −NLR and DFS (HR = 1.01; *p* = 0.738)
  \[[@B24-cancers-12-00958]\]   60.7% ER+ BC\                                                                                                                                                                                                                                                −NLR and PCR (OR = 1.081; *p* = 0.053)                                                                 
                                54.3% PR+ BC\                                                                                                                                                                                                                                                                                                                                                       
                                19.8% HER2+ BC                                                                                                                                                                                                                                                                                                                                                      

  Chen 2016\                    215 patients:\                          Anthracyclines + taxanes (74.9%); anthracyclines (19.1%); taxanes (6%)                                                   NLR as predictive and prognostic factor        2.1                                          NLR^low^ group showed higher PCR rate than NLR^high^ group (24.5% vs 14.3%; *p* \< 0.05)\              +NLR and DFS (HR = 1.57; *p* \< 0.05)\
  \[[@B25-cancers-12-00958]\]   120 luminal A (55.8%)\                                                                                                                                                                                                                                       +NLR and DFS (H = 2.11; *p* \< 0.05)\                                                                  +NLR and BCSS (HR = 2.21; *p* \< 0.05)
                                52 luminal B (24.2%)\                                                                                                                                                                                                                                        +NLR and BCSS (HR = 2.45; *p* \< 0.05)                                                                 
                                25 HER2+ (11.6%)\                                                                                                                                                                                                                                                                                                                                                   
                                18 TNBC (8.4%)                                                                                                                                                                                                                                                                                                                                                      

  Marin-Hernandez 2017\         150 patients:\                          Anthracyclines + taxanes for all patients (except for 3 that received everolimus in the framework of a clinical trial)   Blood parameters as prognostic factors         3.33                                         +NLR and DFS (OR = 0.39; *p* = 0.019)\                                                                 −NLR and DFS (*p* = 0.154)\
  \[[@B26-cancers-12-00958]\]   32 luminal A (21.3%)\                                                                                                                                                                                                                                        +NLR and OS (OR = 0.38; *p* = 0.030)                                                                   −NLR and OS (*p* = 0.543)
                                44 luminal B (29.4%)\                                                                                                                                                                                                                                                                                                                                               
                                35 HER2+ (23.3%)\                                                                                                                                                                                                                                                                                                                                                   
                                39 TNBC (26%)                                                                                                                                                                                                                                                                                                                                                       

  Graziano 2019\                373 patients\                           Anthracyclines + taxanes (56.8%); anthracyclines or taxanes as single agents or in combination                           NLR as predictive factor of PCR                2.42                                         −NLR and PCR (OR = 1.53; *p* = 0.125)\                                                                 
  \[[@B27-cancers-12-00958]\]   132 luminal A (35.4%)\                                                                                                                                                                                                                                       −PLR and PCR (OR = 1.59; *p* = 0.084)                                                                  
                                44 luminal B/HER2− (11.8%)\                                                                                                                                                                                                                                                                                                                                         
                                69 luminal B/HER2+ (18.5%)\                                                                                                                                                                                                                                                                                                                                         
                                62 TNBC (16.6%)\                                                                                                                                                                                                                                                                                                                                                    
                                66 HER2+ (17.7%)                                                                                                                                                                                                                                                                                                                                                    

  Qian 2018\                    180 patients for PCR:\                  Taxane and/or anthracycline-based chemotherapy\                                                                          NLR/PLR as predictive and prognostic factors   2.44                                         +NLR and PCR (20% vs 7.8%; *p* = 0.030)\                                                               −NLR and PCR (*p* = 0.254)
  \[[@B28-cancers-12-00958]\]   24 luminal A (13.3%)\                   Only 40% of patients with HER2+ BC\                                                                                                                                                                                  survival analysis on 131 patients:\                                                                    
                                60 luminal B (33.3%)\                   received trastuzumab                                                                                                                                                                                                 −NLR and DFS (*p* = 0.535) or OS (data not available)                                                  
                                18 HER2+ positive (10%)\                                                                                                                                                                                                                                                                                                                                            
                                40 TNBC (22.2%)\                                                                                                                                                                                                                                                                                                                                                    
                                38 not available (21.2%)\                                                                                                                                                                                                                                                                                                                                           
                                131 patients for survival                                                                                                                                                                                                                                                                                                                                           

  Losada 2018\                  113 \>65-year-old patients:\            Anthracycline, taxanes, or both (no specific data)                                                                       NLR and survival and PCR                       3.33                                         −NLR and DFS (*p* = 0.42) or OS (*p* = 0.38)\                                                          
  \[[@B29-cancers-12-00958]\]   23 luminal A (20.4%)\                                                                                                                                                                                                                                        −NLR and PCR (*p* = 0.43)                                                                              
                                57 luminal B (50.4%)\                                                                                                                                                                                                                                                                                                                                               
                                8 HER2+ (7.1%)\                                                                                                                                                                                                                                                                                                                                                     
                                25 TNBC (22.1%)                                                                                                                                                                                                                                                                                                                                                     

  Koh 2014\                     157 patients with ER/PR+ and HER2− BC   Anthracyclines + taxanes (75.2%); anthracyclines (24.8%)                                                                 NLR as prognostic factor                       2.25                                         +NLR and DFS (HR = 4.01; *p* = 0.001)\                                                                 +NLR and DFS (HR = 3.87; *p* = 0.002)\
  \[[@B30-cancers-12-00958]\]                                                                                                                                                                                                                                                                +NLR and OS (HR = 24.64; *p* = 0.003)                                                                  +NLR and OS (HR = 24.87; *p* = 0.003)

  Chae 2018\                    87 patients with TNBC                   Anthracyclines + taxanes (71.3%); anthracyclines (28.7%)                                                                 NLR as predictive factor of PCR                1.7                                          Patients with low NLR had higher PCR rate (42.1% vs 18.4%; *p* = 0.018)                                +NLR and PCR (OR = 4.27; *p* = 0.008)
  \[[@B31-cancers-12-00958]\]                                                                                                                                                                                                                                                                                                                                                                       
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

NLR: neutrophil to lymphocyte ratio, PLR: platelet to lymphocyte ratio, PCR: pathological complete response, DFS: disease-free survival, OS: overall survival, ER: estrogen receptor, PR: progesterone receptor, BCSS: breast cancer-specific survival, OR: odd ratio, HR: hazard ratio, BC: breast cancer.

cancers-12-00958-t002_Table 2

###### 

Multivariate models (results and adjustment factors) for patients treated with neo-adjuvant chemotherapy.

  All BC Molecular Subtypes                                                               
  ------------------------------------------- ---------- ---------- ---------- ---------- -----------
  Number of multivariate models               1          3          1          1          6
  Number of unique patients                   180        612        150        215        1157
  NLR significantly associated with *n* (%)   0 (0%)     1 (33%)    0 (0%)     1 (100%)   2 (33%)
  Adjustment factors (%)                                                                  
  Hormone receptors                           100        67         NI         100        
  T                                           NI         100        100        100        
  N                                           NI         67         NI         100        
  Age                                         NI         33         100        NI         
  Histological grade                          NI         33         NI         100        
  Molecular subtype                           100        NI         NI         NI         
  Ki67                                        100        NI         NI         NI         
  CRP                                         NI         33         NI         100        
  Surgery method                              NI         33         NI         100        
  Lymphocyte count                            100        33         100        NI         
  Monocyte count                              NI         33         100        NI         
  Neutrophil count                            NI         33         100        NI         
  LMR                                         NI         33         100        NI         
  NMR                                         NI         33         100        NI         
  TNBC                                                                                    
                                              PCR                                         Total
  Number of multivariate models               1                                           1
  Number of unique patients                   87                                          87
  NLR significantly associated with *n* (%)   1 (100%)                                    1 (100%)
  Adjustment factors (%)                                                                  
  Histological subtype                        100                                         
  Histological grade                          100                                         
  Ki67                                        100                                         
  ER+ HER2- BC                                                                            
                                                         DFS        OS                    Total
  Number of multivariate models                          1          1                     2
  Number of unique patients                              157        157                   157
  NLR significantly associated with *n* (%)              1 (100%)   1 (100%)              2 (100%)
  Adjustment factors (%)                                                                  
  PCR                                                    100        100                   
  All studies                                                                             
                                              PCR        DFS        OS         BCSS       Total
  Number of multivariate models               2          4          2          1          9
  Number of unique patients                   267        769        307        215        1558
  NLR significantly associated with *n* (%)   1 (50%)    2 (50%)    1 (50%)    1 (100%)   5 (55.5%)

PCR: pathological complete response, DFS: disease free survival, OS: overall survival, BCSS: breast cancer specific survival, NLR: neutrophil to lymphocyte ratio, LMR: lymphocyte to monocyte ratio, NMR: neutrophil to monocyte ratio, NI: not indicated, T: tumor size, N: node invasion, CRP: C reactive protein.

cancers-12-00958-t003_Table 3

###### 

Articles including data on NLR as prognosis factor in patients with localized BC receiving adjuvant chemotherapy.

  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Author                                            Number of Patients                                 Treatment                                                                                         Primary Objective                          Cut-Off                              Results for the Primary Objective (Univariate Analysis)                              Results of Multivariate Models
  ------------------------------------------------- -------------------------------------------------- ------------------------------------------------------------------------------------------------- ------------------------------------------ ------------------------------------ ------------------------------------------------------------------------------------ ---------------------------------------------------------------
  Noh 2013 \[[@B32-cancers-12-00958]\]              442 patients:\                                     NS                                                                                                NLR as prognostic factor for DSS           2.5                                  +NLR and DSS\                                                                        +NLR and BCSS (HR = 4.08; *p* = 0.003)
                                                    177 luminal A (48.7%)\                                                                                                                                                                                                               5-year survival: 88.6% *vs* 96.4%; 10-year survival: 84.3% *vs* 92.2%; *p* = 0.009   
                                                    69 luminal B (19.0%)\                                                                                                                                                                                                                                                                                                     
                                                    36 HER2+ (10.0%)\                                                                                                                                                                                                                                                                                                         
                                                    81 TNBC (22.3%)                                                                                                                                                                                                                                                                                                           

  Cihan 2014 \[[@B33-cancers-12-00958]\]            350 patients:\                                     CT (94.3%) (based on anthracyclines for 71.7%)                                                    NLR as prognostic factor for DFS and OS    3\                                   −NLR and DFS (0R = 0.8; *p* = 0.410)\                                                
                                                    194 ER+ (55.4%)\                                                                                                                                                                                                                     −NLR and OS (OR = 0.7; *p* = 0.432)                                                  
                                                    183 PR+ (52.3%)\                                                                                                                                                                                                                                                                                                          
                                                    110 HER2+ (31.4%)                                                                                                                                                                                                                                                                                                         

  Forget 2014 \[[@B34-cancers-12-00958]\]           720 patients:\                                     NS                                                                                                NLR as prognostic factor for DFS and OS    3.3                                  +NLR and DFS (HR = 2.20; *p* = 0.004)\                                               +NLR and DFS (HR = 1.99; *p* = 0.010)\
                                                    601 ER+ (83.5%)\                                                                                                                                                                                                                     +NLR and OS (HR = 2.70; *p* = 0.020)                                                 +NLR and OS (HR = 2.35; *p* = 0.046)
                                                    573 PR+ (79.6%)\                                                                                                                                                                                                                                                                                                          
                                                    67 HER2+ (9.3%)                                                                                                                                                                                                                                                                                                           

  Nakano 2014 \[[@B35-cancers-12-00958]\]           167 patients:\                                     NS                                                                                                NLR as prognostic factor for DFS and DSS   2.5\                                 +NLR and DFS (HR = 2.5; *p* = 0.004)\                                                −NLR and DFS (HR = 2.0; *p* = 0.070)\
                                                    130 ER+ (77.8%)\                                                                                                                                                                                (according to previous studies)      +NLR and BCSS (HR = 3.2; *p* = 0.007)                                                +NLR and BCSS (HR=2.7; *p* = 0.045)
                                                    93 PR+ (55.7%)\                                                                                                                                                                                                                                                                                                           
                                                    24 HER2+ (14.4%)                                                                                                                                                                                                                                                                                                          

  Yao 2014 \[[@B36-cancers-12-00958]\]              608 patients:\                                     NS                                                                                                NLR as prognostic factor for OS            2.57                                 −NLR and DFS (*p* = 0.084)\                                                          +NLR and OS (RR = 3.63; *p* = 0.002)
                                                    330 luminal A (57.9%)\                                                                                                                                                                                                               +NLR and OS (*p* \< 0.001)                                                           
                                                    59 luminal B (10.3%)\                                                                                                                                                                                                                                                                                                     
                                                    83 HER2+ (14.6%)\                                                                                                                                                                                                                                                                                                         
                                                    98 TNBC (17.2%)                                                                                                                                                                                                                                                                                                           

  Dirican 2015 \[[@B37-cancers-12-00958]\]          1527 patients:\                                    Adjuvant CT (83.3%),\                                                                             NLR as prognostic factor for DFS and OS    4                                    +NLR and DFS (HR = 2.18; *p* \< 0.001)\                                              +NLR and DFS (HR = 1.46; *p* = 0.028)\
                                                    1019 ER+ (66.4%)\                                  NACT (9.6%)                                                                                                                                                                       +NLR and OS (HR = 2.82; *p* \< 0.001)                                                +NLR and OS (HR = 1.91; *p* = 0.001)
                                                    994 PR+ (64.7%)\                                                                                                                                                                                                                                                                                                          
                                                    249 HER2+ (16.2%)                                                                                                                                                                                                                                                                                                         

  Hong 2016 \[[@B38-cancers-12-00958]\]             487 patients:\                                     Adjuvant CT for 73.5%\                                                                            NLR as prognostic factor for DFS           1.93                                 +NLR and DFS (HR = 2.20; *p* = 0.002)\                                               +NLR and DFS (HR = 1.87; *p* = 0.011)
                                                    62 luminal A (12.7%)\                              (anthracyclines 30.7%; taxanes 15.6%; anthracyclines + taxanes 36%; others 17.7%)                                                                                                 −NLR and 5-year OS (90.8% *vs* 91.7%; *p* = 0.707)                                   
                                                    244 luminal B (50.1%)\                                                                                                                                                                                                                                                                                                    
                                                    59 HER2+ (12.1%)\                                                                                                                                                                                                                                                                                                         
                                                    94 TNBC (19.3%)\                                                                                                                                                                                                                                                                                                          
                                                    28 NA (5.7%)                                                                                                                                                                                                                                                                                                              

  Jia 2015 \[[@B39-cancers-12-00958]\]              1570 patients:\                                    Adjuvant CT (85.4%)                                                                               NLR as prognostic factor for DFS and OS    2.0                                  +NLR and DFS (HR = 1.44; *p* = 0.005)\                                               +NLR and DFS (HR = 1.50; *p* = 0.004)\
                                                    1001 luminal (63.8%)\                                                                                                                                                                                                                +NLR and OS (HR = 1.58; *p* = 0.020)                                                 +NLR and OS (HR = 1.63; *p* = 0.022)
                                                    344 HER2+ (21.9%)\                                                                                                                                                                                                                                                                                                        
                                                    225 TNBC (14.3%)                                                                                                                                                                                                                                                                                                          

  **Author**                                        **Number of Patients**                             **Treatment**                                                                                     **Primary Objective**                      **Cut-Off**                          **Results for the Primary Objective (Univariate Analysis)**                          **Results of Multivariate Models**

  Orditura 2016 \[[@B40-cancers-12-00958]\]         300 patients:\                                     NS                                                                                                NLR as prognostic factor for DFS           1.97                                 +NLR and DFS (HR = 0.45; *p* = 0.034)                                                +NLR and DFS (HR = 2.64; *p* = 0.013)
                                                    77 luminal A (25.7%)\                                                                                                                                                                                                                                                                                                     
                                                    124 luminal B HER2- (41.3%)\                                                                                                                                                                                                                                                                                              
                                                    51 luminal B HER2+ (17%)\                                                                                                                                                                                                                                                                                                 
                                                    21 HER2-enriched (7%)\                                                                                                                                                                                                                                                                                                    
                                                    27 basal like (9%)                                                                                                                                                                                                                                                                                                        

  Ramos-Esquivel 2017 \[[@B41-cancers-12-00958]\]   172 patients:\                                     Adjuvant CT (83.1%), NACT (22.1%)                                                                 NLR as prognostic factor for DFS and OS    3                                    +NLR and DFS (HR = 4.20; *p* \< 0.001)\                                              −NLR and DFS (HR = 1.97; *p* = 0.146)\
                                                    104 ER+ or PR+ and HER2- (60.5%)\                                                                                                                                                                                                    +NLR and OS (HR = 4.20; *p* \< 0.001)                                                −NLR and OS (HR = 1.81; *p* = 0.192)
                                                    18 ER+ or PR+ and HER2+ (10.5%)\                                                                                                                                                                                                                                                                                          
                                                    16 ER− and PR- and HER2+ (9.3%)\                                                                                                                                                                                                                                                                                          
                                                    34 ER− and PR- and HER2− (19.6%)                                                                                                                                                                                                                                                                                          

  Zhang 2016 \[[@B42-cancers-12-00958]\]            162 patients:\                                     NS                                                                                                NLR as prognostic factor for DFS           1.81\                                +NLR and DFS (HR = 1.81; *p* = 0.042)\                                               −NLR and DFS (HR = 1.43; *p* = 0.223)
                                                    87 ER+ (53.7%)\                                                                                                                                                                                 (according to the median value)      −NLR and OS                                                                          
                                                    77 PR+ (47.6%)\                                                                                                                                                                                                                                                                                                           
                                                    37 HER2+ (22.8%)                                                                                                                                                                                                                                                                                                          

  Takeuchi 2017 \[[@B43-cancers-12-00958]\]         296 patients:\                                     Adjuvant CT according to the St Gallen recommendations                                            NLR as prognostic factor for DFS           2.06                                 −NLR and DFS                                                                         
                                                    253 ER+ (85%)\                                                                                                                                                                                                                                                                                                            
                                                    222 PR+ (75%)\                                                                                                                                                                                                                                                                                                            
                                                    247 HER2+ (83%)                                                                                                                                                                                                                                                                                                           

  Cho 2018 \[[@B44-cancers-12-00958]\]              661 patients:\                                     NS                                                                                                NLR as prognostic for DFS and DSS          1.34                                 +NLR and DFS (RR = 1.18; *p* \< 0.001)\                                              −NLR and DFS (RR = 1.24; *p* = 0.613)\
                                                    448 luminal (67.8%)\                                                                                                                                                                                                                 +NLR and DSS (RR = 1.27; *p* \< 0.001)                                               −NLR and BCSS (RR = 1.24; *p* = 0.681)
                                                    96 HER2+ (14.5%)\                                                                                                                                                                                                                                                                                                         
                                                    117 TNBC (17.7%)                                                                                                                                                                                                                                                                                                          

  Ferroni 2018 \[[@B45-cancers-12-00958]\]          475 patients:\                                     NACT (14.1%)\                                                                                     NLR as prognostic factor for DFS and OS    2                                    +NLR and DFS (HR= 2.28; *p* = 0.001)\                                                
                                                    164 luminal A (35%)\                               adjuvant CT (82.5%)\                                                                                                                                                              +NLR and OS (HR = 3.39; *p* = 0.050)                                                 
                                                    239 luminal B (50%)\                               with anthracyclines                                                                                                                                                                                                                                                    
                                                    15 HER2+ (3%)\                                                                                                                                                                                                                                                                                                            
                                                    57 TNBC (12%)                                                                                                                                                                                                                                                                                                             

  Geng 2018 \[[@B46-cancers-12-00958]\]             1374 patients in the testing group:\               96 patients in cohort 1 received NACT                                                             NLR as prognostic factor for DFS           1.878 (in the testing group)         +NLR and DFS testing group (HR = 2.89; *p* \< 0.001)                                 +NLR and DFS in the testing group (HR = 2.99; *p* \< 0.001)
                                                    1038 Hormone receptor+ (75.6%)\                                                                                                                                                                                                                                                                                           
                                                    336 Hormone receptor− (24.4%)\                                                                                                                                                                                                                                                                                            
                                                    128 HER2+ (9.3%)\                                                                                                                                                                                                                                                                                                         
                                                    1246 HER2− (90.7%)\                                                                                                                                                                                                                                                                                                       
                                                    208 TNBC (15.1%)\                                                                                                                                                                                                                                                                                                         
                                                    1166 No TNBC (84.9%)                                                                                                                                                                                                                                                                                                      

  **Author**                                        **Number of Patients**                             **Treatment**                                                                                     **Primary Objective**                      **Cut-Off**                          **Results for the Primary Objective (Univariate Analysis)**                          **Results of Multivariate Models**

  Geng 2018\                                        1084 patients in the validation group:\            NS                                                                                                NLR as prognostic factor for DFS           1.878 (based on the testing group)   +NLR and DFS in the validation group (HR = 1.65; *p* = 0.017)                        +NLR and DFS in the validation group (HR = 1.64; *p* = 0.023)
  \[[@B46-cancers-12-00958]\]                       702 Hormone receptor+ (64.7%)\                                                                                                                                                                                                                                                                                            
                                                    382 Hormone receptor− (35.3%)\                                                                                                                                                                                                                                                                                            
                                                    170 HER2+ (15.7%)\                                                                                                                                                                                                                                                                                                        
                                                    914 HER2− (84.3%)\                                                                                                                                                                                                                                                                                                        
                                                    212 TNBC (19.6%)\                                                                                                                                                                                                                                                                                                         
                                                    872 No TNBC (80.4%)                                                                                                                                                                                                                                                                                                       

  Fujimoto 2018\                                    889 patients:\                                     Adjuvant CT (29.6%)                                                                               NLR as prognostic factor for DFS           2.72                                 +NLR and DFS (HR = 1.56; *p* = 0.047)\                                               −NLR and DFS (*p* = 0.14)
  \[[@B47-cancers-12-00958]\]                       699 ER+ (78.6%)\                                                                                                                                                                                                                     −NLR and OS (*p* = 0.23)                                                             
                                                    152 HER2+ (17.1%)                                                                                                                                                                                                                                                                                                         

  Kim 2016\                                         220 patients with pN3 BC:\                         Adjuvant CT (anthracyclines followed by taxanes) for all patients                                 NLR as prognostic factor for DFS           3\                                   +NLR and 5-year DFS (*p* = 0.043)                                                    +NLR and DFS (HR = 3.93; *p* = 0.020)
  \[[@B48-cancers-12-00958]\]                       99 Hormone receptor+/HER2− (45%)\                                                                                                                                                               (from previous studies)                                                                                                   
                                                    44 Hormone receptor+/HER2+ (20%)\                                                                                                                                                                                                                                                                                         
                                                    48 Hormone receptor−/HER2+ (21.8%)\                                                                                                                                                                                                                                                                                       
                                                    29 TNBC (13.2%)                                                                                                                                                                                                                                                                                                           

  Qiu 2018\                                         406 patients with TNBC                             NACT (21.2%)\                                                                                     NLR as prognostic factor for DFS and OS    2.85                                 +NLR and DFS (HR = 2.63; *p* \< 0.001)\                                              +NLR and DFS (HR = 2.13; *p* = 0.008)\
  \[[@B49-cancers-12-00958]\]                                                                          Adjuvant CT (78.8%)                                                                                                                                                               +NLR and OS (HR = 3.26; *p* \< 0.001)                                                +NLR and OS (HR = 2.69; *p* = 0.001)

  Pistelli 2015\                                    90 patients with TNBC                              NS                                                                                                NLR as prognostic factor for DFS           3                                    +NLR and DFS (*p* = 0.002)\                                                          +NLR and DFS (HR = 5.15; *p* = 0.03)\
  \[[@B50-cancers-12-00958]\]                                                                                                                                                                                                                                                            +NLR and OS (*p* = 0.003)                                                            +NLR and OS (HR = 6.16; *p* = 0.01)

  Lee 2019\                                         358 patients with TNBC                             Adjuvant CT (86.6%): anthracyclines (50.9%), anthracyclines + taxanes (22.4%), others (26.7%).\   NLR as prognostic factor for DFS and OS    3.16                                 +NLR and DFS (HR = 2.11; *p* = 0.036)\                                               −NLR and DFS (*p* = 0.14)\
  \[[@B51-cancers-12-00958]\]                                                                          NACT (14%): anthracyclines + taxanes (64%), anthracyclines (36%)                                                                                                                  +NLR and OS (HR = 2.97; *p* = 0.003)                                                 +NLR and OS (HR = 3.15; *p* = 0.009)

  Patel 2019\                                       126 patients with TNBC                             NACT (31.7%), adjuvant CT (52.4%), or both (4.8%)                                                 NLR as prognostic factor for DFS and OS    NLR: 3\                              −Baseline NLR and DFS (*p* = 0.77)\                                                  
  \[[@B52-cancers-12-00958]\]                                                                                                                                                                                                                       (based on previous studies)          −Baseline NLR and OS (*p* = 0.23)                                                    

  Liu 2016\                                         318 patients with hormone receptor-negative BC:\   Adjuvant CT (81.5%), NACT (17.6%), none (0.9%)                                                    NLR as prognostic factor for DFS and OS    3                                    +NLR and DFS (HR = 2.37; *p* \< 0.001)\                                              +NLR and DFS (HR = 1.89; *p* \< 0.001)\
  \[[@B53-cancers-12-00958]\]                       157 HER2+ (49.4%)\                                                                                                                                                                                                                   +NLR and OS (HR = 3.09; *p* \< 0.001)                                                +NLR and OS (HR = 3.09; *p* \< 0.001)
                                                    161 HER2− (50.6%)                                                                                                                                                                                                                                                                                                         
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

NLR: neutrophil to lymphocyte ratio, PLR: platelet to lymphocyte ratio, PCR: pathological complete response, DFS: disease free survival, OS: overall survival, CT: chemotherapy, NACT: neoadjuvant chemotherapy, ER: estrogen receptor, PR: progesterone receptor, BCSS: breast cancer specific survival, OR: odd ratio, HR: hazard ratio, BC: breast cancer, TNBC: triple negative breast cancer.

cancers-12-00958-t004_Table 4

###### 

Multivariate models (results and adjustment factors) for patients with localized BC receiving adjuvant treatment.

  All BC Molecular Subtypes                                                    
  ------------------------------------------- ----------- ---------- --------- ------------
  Number of multivariate models               13          5          3         21
  Number of unique patients                   9333        4597       1879      15809
  NLR significantly associated with *n* (%)   8 (61.5%)   4 (80%)    2 (66%)   14 (66%)
  Adjustment factor (%)                                                        
  T                                           77          80         33        
  N                                           70          60         100       
  AJCC stage                                  38          40         NI        
  Age                                         31          20         67        
  Menopausal status                           23          NI         NI        
  Hormone receptors                           23          NI         67        
  HER 2 status                                8           NI         NI        
  Molecular subtype                           54          80         NI        
  Histological grade                          38          20         NI        
  LVI                                         8           NI         33        
  Perineural invasion                         NI          NI         33        
  Ki67                                        8           NI         NI        
  Multiplicity                                8           NI         NI        
  Adjuvant chemotherapy                       15          20         NI        
  Endocrine therapy                           8           NI         NI        
  Use of NSAIDs                               8           20         NI        
  PLR                                         15          40         33        
  LMR                                         15          20         33        
  MCH                                         8           NI         NI        
  RDW                                         NI          20         NI        
  dNLR                                        8           NI         33        
  TNBC                                                                         
                                              DFS         OS                   Total
  Number of multivariate models               3           3                    6
  Number of unique patients                   854         854                  1708
  NLR significantly associated with *n* (%)   2 (66%)     3 (100%)             5 (83%)
  Adjustment factor (%)                                                        
  T                                           67          67                   
  N                                           67          67                   
  AJCC stage                                  33          33                   
  Age                                         100         67                   
  Menopausal status                           33          33                   
  Histological subtype                        33          33                   
  Histological grade                          67          67                   
  Ki67                                        33          67                   
  Necrosis                                    33          33                   
  LVI                                         67          67                   
  Type of surgery                             33          33                   
  Adjuvant chemotherapy (vs NACT)             33          33                   
  Adjuvant radiotherapy                       33          33                   
  Cancer recurrence                           NI          33                   
  Hormone receptor-negative BC                                                 
                                              DFS         OS                   Total
  Number of multivariate models               1           1                    2
  Number of unique patients                   318         318                  636
  NLR significantly associated with *n* (%)   1 (100%)    1 (100%)             2 (100%)
  Adjustment factor (%)                                                        
  T                                           100         100                  
  N                                           100         100                  
  Age                                         100         100                  
  Histological grade                          100         100                  
  HER 2 status                                100         100                  
  PLR                                         100         100                  
  All studies                                                                  
                                              DFS         OS         BCSS      Total
  Number of multivariate models               17          9          3         29
  Number of unique patients                   10505       5769       1879      18153
  NLR significantly associated with *n* (%)   11 (65%)    8 (89%)    2 (66%)   21 (72.4%)

CT: chemotherapy, DFS: disease free survival, OS: overall survival, BCSS: breast cancer specific survival, NLR: neutrophil to lymphocyte ratio, NSAIDs: non-steroidal anti-inflammatory drugs, LMR: lymphocyte to monocyte ratio, MCH: mean corpuscular hemoglobin, NMR: neutrophil to monocyte ratio, RDW: red cell distribution width, dNLR: derived NLR, PLR: platelet to lymphocyte ratio, LVI: lympho-vascular invasion, NACT: neoadjuvant chemotherapy, NI: not indicated.

cancers-12-00958-t005_Table 5

###### 

Articles with data on NLR as prognostic factor in patients with metastatic breast cancer.

  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Author                        Number of Patients                                   Treatment                                                                                          Primary Objective                              Cut-Off                         Results for the Primary Objectives (Univariate Analysis)       Results of Multivariate Models
  ----------------------------- ---------------------------------------------------- -------------------------------------------------------------------------------------------------- ---------------------------------------------- ------------------------------- -------------------------------------------------------------- -------------------------------------------------------------
  Iwase 2017\                   89 patients with recurrent BC after surgery:\        NS                                                                                                 NLR and prognosis                              3 (based on previous studies)   +NLR and OS (HR = 2.68; *p* \< 0.05)                           +NLR and OS (HR = 2.93; *p* \> 0.05)
  \[[@B54-cancers-12-00958]\]   31 ER+ HER2− (35%)\                                                                                                                                                                                                                                                                                   
                                20 ER+ HER2+ (22%)\                                                                                                                                                                                                                                                                                   
                                14 HER2 type (16%)\                                                                                                                                                                                                                                                                                   
                                24 TNBC (27%)                                                                                                                                                                                                                                                                                         

  Araki 2018\                   51 patients with HER2+ BC:\                          Pertuzumab\                                                                                        Blood-based prognostic parameters              2\                              −NLR and PFS                                                   
  \[[@B55-cancers-12-00958]\]   14 ER+ (47%)\                                        and trastuzumab combined with eribulin (ERI) (*n* = 30) or nab-paclitaxel (*n* = 21)                                                              (median value)                                                                                 
                                5 PR+ (17%)                                                                                                                                                                                                                                                                                           

  Miyagawa 2018\                85 patients:\                                        Eribulin (*n* = 59) or nab-paclitaxel (*n* = 26)                                                   NLR and prognosis according to the treatment   3\                              +NLR and PFS in the eribulin group (HR = 0.37; *p* = 0.003)\   +NLR and PFS in the eribulin group (HR = 0.39; *p* = 0.007)
  \[[@B56-cancers-12-00958]\]   62 ER+ (73%)\                                                                                                                                                                                          (based on previous studies)     −NLR and PFS in the nab-paclitaxel group (*p* = 0.84)\         
                                39 PR+ (46%)\                                                                                                                                                                                                                          −NLR and OS in the eribulin group (*p* = 0.058)\               
                                4 HER2+ (5%)                                                                                                                                                                                                                           −NLR and OS in the nab-paclitaxel group (*p* = 0.15)           

  De Sanctis 2018\              71 patients:\                                        Eribulin (after 2 to 5 previous lines of chemotherapy)                                             NLR as prognostic factor                       2.5--4--5.5                     −NLR and PFS (*p =* 0.5) for any cut-off value                 
  \[[@B57-cancers-12-00958]\]   53 hormone receptor+ (75%)\                                                                                                                                                                                                                                                                           
                                8 HER2+ (11%)\                                                                                                                                                                                                                                                                                        
                                11 TNBC (15%)                                                                                                                                                                                                                                                                                         

  Takuwa 2018\                  171 patients:\                                       NS                                                                                                 NLR as prognostic factor                       1.9                             +NLR and OS (33 vs 79 months, *p* = 0.004)                     +NLR and OS (HR = 1.75; *p* = 0.022)
  \[[@B58-cancers-12-00958]\]   93 ER+ HER2− (54.4%)\                                                                                                                                                                                                                                                                                 
                                23 ER+ HER2+ (13.5%)\                                                                                                                                                                                                                                                                                 
                                20 ER− HER2+ (11.7%)\                                                                                                                                                                                                                                                                                 
                                28 ER− HER2− (16.4%)\                                                                                                                                                                                                                                                                                 
                                7 unknown (4.0%)                                                                                                                                                                                                                                                                                      

  Author                        Number of patients                                   Treatment                                                                                          Primary objective                              Cut-off                         Results for the primary objectives (univariate analysis)       Results of multivariate models

  Iimori 2018\                  34 patients receiving ET as initial drug therapy:\   Endocrine therapy:\                                                                                NLR as predictive factor of the response to\   3\                              +NLR and PFS (HR = 3.94; *p* = 0.016)\                         +NLR and PFS (HR = 3.93; *p* = 0.008)
  \[[@B59-cancers-12-00958]\]   4 HER2+ (12%)                                        letrozole (58.8%); anastrozole (20.6%); tamoxifen (with/without LHRH) (17.7%); exemestane (2.9%)   endocrine therapy and prognosis                (based on previous studies)     +NLR and OS (*p* = 0.013)\                                     
                                                                                                                                                                                                                                                                       +NLR and time to treatment failure (*p* = 0.031)               

  Vernieri 2018\                57 patients with TNBC                                Platinum-based chemotherapy: carboplatin-paclitaxel (84%)\                                         NLR as prognostic factor                       2.5\                            +NLR and PFS (HR = 3.25; *p* \< 0.001)                         +NLR and PFS (HR = 2.65; *p* = 0.004)
  \[[@B60-cancers-12-00958]\]                                                        or carboplatin-gemcitabine (16%);\                                                                                                                (based on previous studies)                                                                    
                                                                                     first line (88%) or second line (12%)                                                                                                                                                                                                            

  Imamura 2019\                 53 patients with HER2+ BC                            TDM-1                                                                                              NLR as prognostic factor                       2.56                            +NLR and PFS (HR = 0.23; *p* \< 0.001)\                        +NLR and PFS (HR = 0.27; *p* = 0.0019)\
  \[[@B61-cancers-12-00958]\]                                                                                                                                                                                                                                          +NLR and OS (HR = 0.38; *p* = 0.0296)                          +NLR and OS (HR = 0.35; *p* = 0.018)
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

NLR: neutrophil to lymphocyte ratio, PLR: platelet to lymphocyte ratio, PCR: pathological complete response, DFS: disease-free survival, OS: overall survival, ER: estrogen receptor, PR: progesterone receptor, BCSS: breast cancer-specific survival, OR: odd ratio, HR: hazard ratio, BC: breast cancer, ET: endocrine therapy, TNBC: triple negative breast cancer.

cancers-12-00958-t006_Table 6

###### 

Multivariate models (results and adjustment factors) for patients with metastatic breast cancer.

  All BC Molecular Subtypes                                         
  ------------------------------------------- ---------- ---------- ----------
  Number of multivariate models               1          2          3
  Number of unique patients                   85         260        345
  NLR significantly associated with n (%)     1 (100%)   2 (100%)   3 (100%)
  Adjustment factor (%)                                             
  Menopausal status                           NI         50         
  BMI                                         NI         50         
  Molecular subtype                           NI         50         
  LDH                                         NI         50         
  Complete response                           NI         50         
  Primary tumor stage IV                      NI         50         
  Number of metastatic sites                  NI         50         
  Visceral metastasis sites (≥2 vs \<2)       NI         50         
  Previous chemotherapy                       100        NI         
  Hormone receptor-positive BC                                      
                                              PFS                   Total
  Number of multivariate models               1                     1
  Number of unique patients                   34                    34
  NLR significantly associated with *n* (%)   1 (100%)              1 (100%)
  Adjustment factor (%)                                             
  Objective response to endocrine therapy     100        NI         
  TNBC                                                              
                                              PFS                   Total
  Number of multivariate models               1                     1
  Number of unique patients                   57                    57
  NLR significantly associated with n (%)     1 (100%)              1 (100%)
  Adjustment factor (%)                                             
  Visceral metastases                         100        NI         
  Maintenance chemotherapy                    100        NI         
  Previous exposure to taxanes                100        NI         
  PLR                                         100        NI         
  HER 2+ BC                                                         
                                              PFS        OS         Total
  Number of multivariate models               1          1          2
  Number of unique patients                   53         53         106
  NLR significantly associated with *n* (%)   1 (100%)   1 (100%)   2 (100%)
  Adjustment factor (%)                                             
  Disease control during 1^st^ line therapy   100        100        
  Number of metastatic sites                  100        100        
  All patients                                                      
                                              PFS        OS         Total
  Number of multivariate models               4          3          7
  Number of unique patients                   229        313        542
  NLR significantly associated with *n* (%)   4 (100%)   3 (100%)   7 (100%)

PFS: progression-free survival, OS: overall survival, NLR: neutrophil to lymphocyte ratio, PLR: platelet to lymphocyte ratio, BMI: body mass index, NI: not indicated, LDH: dehydrogenase lactate.

cancers-12-00958-t007_Table 7

###### 

Articles with data on inflammatory blood markers as predictive factor of toxicity in patients with breast cancer.

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Author                                         Number of Patients        Population of Interest                                                                                                                                                        Treatment                                Primary Objective                                                                                                               Cut-Off                                           Results for the Primary Objective (Univariate Results)                                            Results of Multivariate Models
  ---------------------------------------------- ------------------------- ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ---------------------------------------- ------------------------------------------------------------------------------------------------------------------------------- ------------------------------------------------- ------------------------------------------------------------------------------------------------- --------------------------------------------------------------------
  Ray Coquard 2001 \[[@B62-cancers-12-00958]\]   1051                      First-line chemotherapy (BC, colon, ovary, head and neck, lung, other cancer type)                                                                                            NS                                       To establish a risk model for early death after chemotherapy (defined as death within 1 month after treatment administration)   Lymphocytes \<0.7 G/L                             Predictive of early death:\                                                                       Predictive of early death: day 1 lymphocytes \< 0.7 G/L (OR = 3.1)
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    day 1 lymphocyte count \<0.7 G/L (*p* \< 0.01)\                                                   
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    day 1 platelet count \<150 G/L (*p* = 0.01)                                                       

  Ray Coquard 2003 \[[@B63-cancers-12-00958]\]   3 groups:\                All cancers (BC, colon-rectum, ovary, head and neck, lung, lymphoma, myeloma, sarcoma, germ cell tumors, other) treated by chemotherapy (regardless of previous treatments)   NS                                       To evaluate a risk model\                                                                                                       Lymphocytes \<0.7 G/L                             In the CLB-1996 cohort:\                                                                          Lymphocytes at day 1 and FN (OR = 1.75; *p* = 0.02)
                                                 −950 (CLM-1996 cohort)\                                                                                                                                                                                                                          for FN using only day 1 blood cell count, and to compare the day 1 and day 5 risk models                                                                                          +lymphocytes at day 1 and FN (*p* = 0.05)\                                                        
                                                 −321 (Elypse 1 cohort)\                                                                                                                                                                                                                                                                                                                                                                                                            Lymphocytes at day 5 and FN data not available in the Elypse 1 cohort:\                           
                                                 −329 (Elypse 0 cohort)                                                                                                                                                                                                                                                                                                                                                                                                             −lymphocytes at day 1 and FN (*p* = 0.18)\                                                        
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    +lymphocytes at day 5 and FN (*p* \< 0.01)\                                                       
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    In the Elypse 0 cohort:\                                                                          
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    −lymphocytes at day 1 and FN (*p* = 0.08)\                                                        
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    +lymphocytes at day 5 and FN (*p* \< 0.01)                                                        

  Choi 2003\                                     82                        All cancers (non-Hodgkin lymphoma, stomach, BC, NSCLC, hepatobiliary, sarcoma, colorectal cancer and others) receiving first course of chemotherapy                           NS                                       To evaluate lymphocyte count at day 1, day 3 and day 5 as a way to identify patients at risk of FN                              Lymphocytes \<0.7 G/L and lymphocytes \<0.5 G/L   For lymphocytes ≤0.5 G/L:\                                                                        Day 5 lymphocytes ≤ 0.7 G/L and NF (OR = 19.0 *p* = 0.01)
  \[[@B64-cancers-12-00958]\]                                                                                                                                                                                                                                                                                                                                                                                                                                                       −day 1 and FN (*p* = 0.33)\                                                                       
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    +day 3 and FN (*p* \< 0.01)\                                                                      
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    +day 5 and FN (*p* = 0.023)\                                                                      
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    For lymphocytes ≤ 0.7 G/L:\                                                                       
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    −day 1 and FN (*p* = 0.05)\                                                                       
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    +day 3 and FN (*p* = 0.01)\                                                                       
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    +day 5 and FN (*p* \< 0.01)                                                                       

  Yamanouchi 2017 \[[@B65-cancers-12-00958]\]    67                        BC, all stages (only 6% stage IV)                                                                                                                                             Docetaxel 75 mg/m^2^ at least 4 cycles   To elucidate the relationship between PN and NLR, PLR and MLR                                                                   Median NLR in patients with or without toxicity   No correlation between NLR, PLR, or MLR before or at the first or third cycle and PN occurrence   
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

NLR: neutrophil to lymphocyte ratio, PLR: platelet to lymphocyte ratio, MLR: monocyte to lymphocyte ratio, OR: odd ratio, BC: breast cancer, FN: febrile neutropenia, PN: peripheral neuropathy.
